Featured Post from ChristianaCare

ChristianaCare Rated a High Performing Hospital for Maternity by U.S. News & World Report

Dec 7, 2022

5 min

ChristianaCare is the only health system in Delaware to earn the High Performing designation from U.S. News


ChristianaCare has earned the highest award for maternity care that a hospital can achieve from U.S. News & World Report in its 2022-23 ratings for Best Hospitals for Maternity Care.


Rated as a High Performing Hospital, ChristianaCare was the only health system in Delaware to earn this esteemed honor. Christiana Hospital at ChristianaCare’s Newark Campus is the only high-risk delivering hospital in the First State offering Level III neonatal intensive care. More than 6,100 babies are born at Christiana Hospital each year.


The U.S. News Best Hospitals for Maternity Care methodology is based entirely on objective measures of quality, such as C-section rates in lower-risk pregnancies, newborn complication rates, exclusive breast milk feeding rates, early elective delivery rates and vaginal birth after cesarean (VBAC) rates, among other measures.


“When we announced plans seven years ago to build the ChristianaCare Center for Women’s & Children’s Health, we affirmed our commitment to provide superior-quality care for women and infants in our region,” said Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at ChristianaCare. “This prestigious recognition is an affirmation that patients who choose to give birth at ChristianaCare will have access to the very best services and expertise to ensure a safe delivery and a healthy baby.”


Just two years ago ChristianaCare opened the Center for Women’s & Children’s Health, an eight-story, approximately 400,000-square-foot tower at Christiana Hospital. The center uses the most up-to-date, evidence-based models of care, with improved integration of services and the space to offer innovative patient-centered care for mothers, babies and families.


One of the most significant features of the new center is a state-of-the-art neonatal intensive care unit (NICU), featuring private rooms with sleep-in space for families. Christiana Hospital is one of the only hospitals in the United States to provide “couplet care” in the NICU, keeping the mother and baby together even if they both require medical care. This is based on a European model demonstrating that moms are more likely to breastfeed in this environment, which is particularly important in the early development of children.


“We best achieve optimal health and flourish when we are able to begin our lives as healthy newborns,” said David Paul, M.D., chair of ChristianaCare’s Department of Pediatrics. “Building this transformative women’s and children’s hospital was a way to invest in the future of our community’s children. In addition to our outstanding caregivers and the care we provide within the walls of the hospital, this facility is a monumental step forward in enabling us to care for moms and babies, and we are delighted that U.S. News has recognized what a special place it is.”


Other innovative features at the center include:

  • Expanded labor and delivery suites.
  • Private rooms for mothers and families after delivery.
  • A spacious, multi-level Ronald McDonald Family Room to support families with infants who are in intensive care.
  • Expanded OB/GYN emergency services area and new labor lounge.
  • Separate admitting and discharge areas for the convenience of our patients.
  • A tranquil family rooftop garden that provides spaces for play and relaxation.
  • Vibrant sibling play spaces with interactive displays and artwork, and open community spaces for health education and programs.


U.S. News’ annual evaluation is designed to assist expectant parents and their doctors in making informed decisions about where to receive maternity care.


U.S. News evaluated nearly 650 hospitals that provide high-quality labor and delivery services for uncomplicated pregnancies for its 2022-2023 Best Hospitals for Maternity Care. Fewer than half of all hospitals that offer maternity care and participated in the survey received a High Performing designation.


“When expectant parents are considering their options for welcoming a baby to the world, the Best Hospitals for Maternity Care are designed to help them identify hospitals that excel in delivering babies for uncomplicated pregnancies,” said Ben Harder, chief of health analysis and managing editor at U.S. News & World Report. “A hospital that has earned a High Performing designation may be a good option for parents, in consultation with their medical provider, to consider.”


Excellence in Maternity Care Built on Experience and Research


ChristianaCare’s Center for Women’s & Children’s Health includes Delaware’s most experienced maternity team, and it is also a significant research institution.


Since opening, the Center for Women’s & Children’s Health participated in a significant study that found that treating mild chronic hypertension with medications is beneficial and safe for mother and baby. Published in The New England Journal of Medicine, the world’s foremost medical journal, the study has the potential to change the standard of care for some pregnant women, as it represented the first time that comprehensive, evidence-based data showed the benefits of treating mild forms of chronic hypertension during pregnancy.


“Our commitment to research is a path to better caring for our community,” said Dr. Hoffman, a co-author in the study.


About ChristianaCare

Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,299 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute.


ChristianaCare is nationally recognized as a great place to work, rated by Forbes as the 2nd best health system for diversity and inclusion, and the 29th best health system to work for in the United States, and by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is rated by Healthgrades as one of America’s 50 Best Hospitals and continually ranked among the nation’s best by U.S. News & World Report, Newsweek and other national quality ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.





Powered by

You might also like...

Check out some other posts from ChristianaCare

3 min

New Study Finds Most Patients Can Safely Continue Weight Loss and Diabetes Drugs Before Gynecologic Surgery

Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”

1 min

Two Research Scientists at the Cawley Center for Translational Cancer Research Earn Top Honors at UD Biology Research Day

Two rising cancer researchers from ChristianaCare’s Cawley Center for Translational Cancer Research were recognized for outstanding scientific contributions at the University of Delaware’s Annual Biology Research Day Conference on January 30, 2026. The awards highlight the strength and impact of colorectal cancer research underway at the Cawley Center. Anh Nguyen, a third year Ph.D. student, received the conference’s first place poster award for his project, “FGF19/FGFR4 Axis: A Key Driver in Tumor Growth and Treatment Resistance in Colorectal Cancer.” His research explores a signaling pathway that may lead to new strategies for targeting treatment resistant disease. Molly Lausten, a fifth year Ph.D. student, earned third place for her presentation, “Investigating the role of miR 27a 3p in the WNT signaling pathway and chemoresistance in colorectal cancer stem cells.” Her work examines a key microRNA that may influence resistance to therapy, a major challenge in treating aggressive tumors. “These awards reflect far more than individual excellence,” said Bruce M. Boman, M.D., Ph.D., MSPH, FACP, senior scientist and director of Cancer Genetics at the Cawley Center. “They show the power of rigorous, curiosity driven science to move the field forward. Molly and Anh are tackling some of the hardest questions in colorectal cancer, and their success speaks to the innovative environment we are building at ChristianaCare. I could not be more proud of their achievement and their commitment to improving outcomes for patients.”

3 min

Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients

Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”

View all posts
Powered by